VC
PCRX icon

VarCov Co’s Pacira BioSciences PCRX Stock Holding History

VarCov Co’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$549K Buy
+21,650
New +$512K 0.21% 170

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

VarCov Co's PCRX Position: Q2 2026 in Review

VarCov Co opened a new position in Pacira BioSciences (PCRX) in Q2 2026: 21,650 shares worth $549K. The stake represents 0.21% of the portfolio and ranks #170 among its holdings.

251 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • VarCov Co held 21,650 shares of Pacira BioSciences worth $549K as of Q2 2026.
  • Pacira BioSciences was a new VarCov Co position in Q2 2026.
  • Pacira BioSciences made up 0.21% of VarCov Co's portfolio in Q2 2026, its #170 holding.
  • 251 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on VarCov Co's 13F filing for Q2 2026, filed 14 Aug 2026.